Congress to Clinic: Continual Evolution of HER3 Targeting in NSCLC With Expert Perspectives on Clinical Advances and Practical Application

Explore expert insights on the newest data on use of HER3-targeted therapy for patients with advanced NSCLC. Listen to podcasts derived from a live event, and download the accompanying slides for a comprehensive reference on the latest advancements in clinical trials.

Share

Program Content

Activities

HER3-Targeted Therapy in NSCLC
Congress to Clinic: Continual Evolution of HER3-Targeting in NSCLC With Expert Perspectives on Clinical Advances and Practical Application
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 17, 2023

Activities

HER3 Trials in NSCLC
Unpacking the Potential of HER3-Targeted Therapy in NSCLC
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 26, 2023

AE Management for HER3-Targeted Tx
Current Considerations for Adverse Event Management With HER3-Directed Agents
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 26, 2023

Rationale for Targeting HER3 in NSCLC
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 26, 2023

Faculty

cover img faculity

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.